Posted by AGORACOM-JC
at 12:34 PM on Tuesday, April 20th, 2021
Will present at the Planet MicroCap Showcase: VIRTUAL on Thursday, April 22 nd at 12:00 PM EDT
MedX Health Corp. (TSXV: MDX) (“ MedX ” or the “ Company ”), a global leader in teledermatology, will present at the Planet MicroCap Showcase: VIRTUAL on Thursday, April 22 nd at 12:00 PM EDT.
Mike Druhan, President of Dermatology Services, will present at the event, outlining MedX’s vision for scaling access to its unique dermatological image capture technology and its fully integrated telemedicine platform, DermSecure®. Unlike other teledermatology screening tools available, MedX’s DermSecure® Screening Platform features high-resolution image capture technology for moles, lesions and other skin conditions, providing a complete, virtual dermatological assessment by a certified dermatologist within just 72 hours.
To access the live presentation, please use the following details:
To book a one-on-one investor meeting with MedX or to watch the Company’s presentation, please register for the virtual event here: https://planetmicrocapshowcase.com/signup
One-on-one meetings will be scheduled and conducted via private, secure video conference through the conference event platform.
For those unable to attend the live presentation, all company presentation webcasts will be available directly on the conference event platform on this link under the tab “Agenda”: https://planetmicrocapshowcase.com/agenda
About MedX
MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also embedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain-free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA, TGA and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain.
SNN.Network is your multimedia financial news platform for discovery, transparency and due diligence. This is your one-stop hub to find new investment ideas, check in on watchlist, gather the most up-to-date information on the Small-, Micro-, Nano-Cap market with the goal to help you towards achieving your wealth generation goals. Follow the companies you want to know more about; read and watch content from your favorite finance and investing influencers; create your own watchlist and screen for ideas you’re interested in; find out about investor conferences you want to attend – all here on SNN.Network.
Posted by AGORACOM-JC
at 6:23 PM on Thursday, March 18th, 2021
To understand the power of this Pilot program between Empower Clinics and MedX Health, you simply have to read the following … don’t gasp.
“With only about 500 dermatologists available to serve over 37 million Canadians, the wait times to see a specialist in-person can be anywhere from five months to one year,” said Mike Druhan, President, Dermatology Services, MedX Health Corp. “The COVID-19 pandemic has nearly doubled the average wait period. We know that early detection of melanoma greatly increases the patient’s survival rate and reduces the cost to the health-care system. Partnering with Empower allows us to dramatically grow our patient base, and ultimately save more lives.”
If at first you thought this was only about pimples and dry skin, nobody could blame you. But the fact of the matter is that over 80,000 cases of skin cancer are diagnosed in Canada each year and more than 5,000 of these are melanoma, the deadliest form of skin cancer.
Unfortunately, due to the shocking shortage of dermatologists in Canada, many people are discovering melanomas too late and either dying or going through excruciating late-stage treatments that could have been treated by simple removal months earlier.
Empower Clinics in the midst of a national clinic rollout strategy that includes a partnership with Rexall to integrate health care centres right into some of their locations. MedX Health, is in the midst of a global rollout with deals already signed in Brazil, Netherlands and Mexico … but not right in its backyard here in Canada.
Together the two companies are a powerful force and, if all goes well with the pilot over the next 4 months, will save untold lives by giving easy and fast access to Canadians who can complete a virtual dermatological assessment by a certified dermatologist within just 72 hours.
How is that for a game changer?
Watch this great interview with Empower CEO Steve McAuley and MedX Health President of Dermatological Services, Mike Druhan.
Posted by AGORACOM-JC
at 9:32 AM on Tuesday, March 2nd, 2021
Announce the appointment of veteran healthcare industry executive Paul Karam as Sales and Marketing Director, Europe, Middle East & Africa
Initially, Mr. Karam will be supporting the rollout and expansion in Turkey, Saudi Arabia, The United Arab Emirates and South Africa
He will also be responsible for new ventures and partnerships across the MEA Region and developing and executing the company marketing strategy in the EMEA region.
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX), a global leader in teledermatology, is pleased to announce the appointment of veteran healthcare industry executive Paul Karam as Sales and Marketing Director, Europe, Middle East & Africa (“EMEA”), effective immediately. Mr. Karam will be reporting to the Managing Director for the EMEA region and strengthening the MedX global footprint in general and EMEA presence in particular.
Mr. Karam holds a master’s degree in Biomedical Engineering from the University of Surrey in the United Kingdom. He brings 20 plus years of experience in the health care industry, where he has held several leading roles within multinational companies covering Central and Eastern Europe, Turkey, the Middle East, Africa and Pakistan markets. He has a career history with Medtronic, Molnlycke, Stryker, and several other global companies.
“Mr. Karam’s strong experience and skills will be of high added value to our overall strategy in the region, as he helps develop the EMEA region with a specific focus on Turkey, the Middle East and African sub-regions. Mr. Karam will play an integral part in accelerating MedX’s revenue growth prospects by activating his already well-established medical device distributors network to the benefit of MedX’s skin assessment telemedicine technology in the region,” said Mr. Naman Demaghlatrous, Managing Director for EMEA.
Initially, Mr. Karam will be supporting the rollout and expansion in Turkey, Saudi Arabia, The United Arab Emirates and South Africa. He will also be responsible for new ventures and partnerships across the MEA Region and developing and executing the company marketing strategy in the EMEA region.
“We are pleased to welcome Paul to the MedX team. We are fortunate to attract a person of his calibre, and I think it speaks to the strength of our offering and the opportunity it presents in the EMEA market,” stated Michael Druhan, President of Dermatological Services & Products.
Posted by AGORACOM-JC
at 9:11 AM on Thursday, February 25th, 2021
Closed on the final $1.4 million of the $4 million Non-brokered Private Placement of 80 Convertible Debenture Loan Notes
Each with a face value of $50,000, as originally announced in its Press Release dated January 25, 2021. Previous Closings were announced earlier in February 2021
MedX Health Corp. (“ MedX ” or the “ Company ”) (TSX-V: MDX) is pleased to announce that it has closed on the final $1.4 million of the $4 million Non-brokered Private Placement of 80 Convertible Debenture Loan Notes, each with a face value of $50,000 (“Convertible Notes”), as originally announced in its Press Release dated January 25, 2021. Previous Closings were announced earlier in February 2021.
Full Details of each of the Closings are as follows:
First Closing on January 27, 2021: $2 million, with cash commissions of $114,000 and issuance of 300,000 Broker Warrants;
Second Closing on January 28, 2021: $500,000, with cash commissions of $15,000 and issuance of 107,143 Brokers Warrants;
Third Closing on February 3, 2021: $100,000, with no cash commissions and no Brokers Warrants;
Fourth, and final Closing, on February 23, 2021: $1.4 million, with cash commissions of $81,000 and issuance of 578,576 Brokers Warrants.
The Convertible Notes will bear interest at 6% per year, payable Quarterly, and will mature on December 31, 2023 (the “Maturity Date”). The Convertible Notes may be converted, at the option of the Holder, into units at $0.14 per unit (“Unit”) at any time until the Maturity Date. Each Unit will be comprised of One (1) fully paid Common Share and One-half (1/2) of a Share Purchase Warrant. Each whole Share Purchase Warrant will be exercisable to purchase One (1) further Common Share at the price of $0.20, exercisable for a period expiring on the Maturity Date. The Convertible Notes, and any underlying securities, are subject to restriction from trading for a period of 4 months and one day from the respective dates of issuance. Qualified Agents received commissions in respect of subscriptions introduced by them by way of cash equal to 6% of funds so introduced, and issuance of agent’s warrants (“Agent’s Warrant(s)”) calculated by reference to 6% of the funds from subscribers introduced by such Agent. Each Agent’s Warrant, which is non-transferable, will be exercisable to acquire one Unit at $0.14 per Unit, at any time during the period up to the Maturity Date. A total of $210,000 of cash commissions were paid, and 985,719 Agent’s Warrants have been issued. The Agent’s Warrants, and any underlying securities, are restricted from trading for a period of four months and one day from their respective dates of issuance.
MedX’s CEO, Rob von der Porten stated, “We believe this financing clearly demonstrates a vote of confidence in our strategic direction and ability to be a leader in the teledermatology space. This funding is significant to furthering the development of our sales initiatives and advancing MedX’s Dermsecure TM platform to a wider global network.”
About MedX
MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy on DermSecure™ telemedicine platform, utilizing its SIAscopy™ technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA, TGA and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union, Turkey and Brazil. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.
Posted by AGORACOM-JC
at 8:44 AM on Monday, February 1st, 2021
Closed on the first $2.5 million of the $4 million Non-brokered Private Placement of Convertible Debenture Loan Notes each with a face value of $50,000 as originally announced in its Press Release dated January 25, 2021.
On January 27 and 28, 2021, there were closings of 40 and 10 Convertible Notes respectively, raising gross proceeds of $2.5 million.
MedX Health Corp. (“ MedX ” or the “ Company ”) (TSX-V: MDX) is pleased to announce that it has closed on the first $2.5 million of the $4 million Non-brokered Private Placement of Convertible Debenture Loan Notes each with a face value of $50,000 (“Convertible Notes”) as originally announced in its Press Release dated January 25, 2021. On January 27 and 28, 2021, there were closings of 40 and 10 Convertible Notes respectively, raising gross proceeds of $2.5 million. The Convertible Notes will bear interest at 6% per year, payable Quarterly, and will mature on December 31, 2023 (the “Maturity Date”). The Convertible Notes may be converted, at the option of the Holder, into units at $0.14 per unit (“Unit”) at any time until the Maturity Date. Each Unit will be comprised of One (1) fully paid Common Share and One-half (1/2) of a Share Purchase Warrant. Each whole Share Purchase Warrant will be exercisable to purchase One (1) further Common Share at the price of $0.20, exercisable for a period expiring on the Maturity Date. The Company anticipates that it will close on further issuances of up to 30 more Convertible Notes, for up to a further $1.5 million. Closings will be subject to receipt of subscriptions and a number of other conditions, including without limitation the receipt of all relevant regulatory and Stock Exchange approvals or acceptances. The Convertible Notes, and any underlying securities, are subject to restriction from trading for a period of four months and one day from the respective dates of issuance. Qualified Agents may receive commissions in respect of subscriptions introduced by them by way of cash equal to 6% of funds so introduced, and issuance of agent’s warrants (“Agent’s Warrant(s)”) calculated by reference to 6% of the funds from subscribers introduced by such Agent. Each Agent’s Warrant, which is non-transferable, will be exercisable to acquire one Unit at $0.14 per Unit, at any time during the period up to the Maturity Date. In relation to the Closings already completed, a total of $129,000 has been paid by way of cash commissions and 407,143 Agent’s Warrants were issued. The Agent’s Warrants, and any underlying securities, are restricted from trading for a period of four months and one day from their respective dates of issuance.
Posted by AGORACOM-JC
at 3:42 PM on Thursday, December 31st, 2020
Will be presenting at the SNN Network Canada Virtual Event on Thursday, January 7th at 5:00 PM EST.
Mike Druhan, President of Dermatology Products & Services, will host the presentation and answer investors’ questions.
MISSISSAUGA, ON / December 31, 2020 / MedX Health Corp. (TSXV:MDX)(“MedX” or “the Company“), a global leader in teledermatology, will be presenting at the SNN Network Canada Virtual Event on Thursday, January 7th at 5:00 PM EST. Mike Druhan, President of Dermatology Products & Services, will host the presentation and answer investors’ questions.
To access the live presentation, please use the following information:
Mr. Druhan will provide an overview of MedX’s unique image capture technology and its fully integrated telemedicine platform. MedX specializes in the Dermatology market. Included in the presentation will be MedX’s commercialization strategy and its SaaS financial model.
If you would like to book one-on-one investor meetings with MedX Health and to watch the MedX presentation, please make sure you are registered for the virtual event here: https://canada.snn.network/signup
One-on-one meetings will be scheduled and conducted via private, secure video conference through the conference event platform.
For those unable to attend the live presentation, all company presentation “webcasts” will be available directly on the conference event platform on this link under the tab “Agenda”:
About MedX MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also embedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain-free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA, TGA and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain.
About SNN.Network SNN.Network is your multimedia financial news platform for discovery, transparency and due diligence. This is your one-stop hub to find new investment ideas, check in on watchlist, gather the most up-to-date information on the Small-, Micro-, Nano-Cap market with the goal to help you towards achieving your wealth generation goals. Follow the companies YOU want to know more about; read and watch content from YOUR favorite finance and investing influencers; create your own watchlist and screen for ideas you’re interested in; find out about investor conferences you want to attend – all here on SNN.Network.
Posted by AGORACOM-JC
at 8:13 AM on Monday, December 21st, 2020
Nationally renowned dermatologist will lead advanced product development & innovation
Announced the appointment of Dr. Trevor Champagne as Chair of the Company’s Medical Advisory Board.
A member of the Advisory Board since 2018—among other distinguished members and world-class dermatologists Dr. Daniel Siegel, Dr. Per Hall, Dr. Joe Walls, and Dr. Dennis Reich—Dr. Champagne has helped position MedX as a leader in teledermatology.
MedX Health Corporation (“MedX” or the “Company”) (TSX-V: MDX), is pleased to announce the appointment of Dr. Trevor Champagne as Chair of the Company’s Medical Advisory Board. A member of the Advisory Board since 2018—among other distinguished members and world-class dermatologists Dr. Daniel Siegel, Dr. Per Hall, Dr. Joe Walls, and Dr. Dennis Reich—Dr. Champagne has helped position MedX as a leader in teledermatology.
Teledermatology is a subspecialty of dermatology that offers safe and effective virtual care—patient assessment and diagnosis—at a distance, eliminating the need for in-person appointments. With the world navigating through ongoing COVID-19 recovery measures, teledermatology’s advancement has never been more critical to patient care and outcomes. Dr. Champagne will drive ongoing innovation with MedX’s teledermatology offering, including the Company’s leading-edge image capture technology (SIAscopy®) for moles, lesions and other skin conditions via its secure, cloud-based patient management system (DermSecure®), which transmits and stores patient data through the assessment process. MedX’s SIAscopy® is the only technology that takes five images, including four spectrophotometric images 2 mm below the skin’s surface.
In addition to his leadership appointment at MedX, Dr. Champagne is a dermatologist at the Women’s College Hospital in Toronto, as well as an Assistant Professor (Clinician in Quality and Innovation, Division of Dermatology) at the University of Toronto’s Temerty Faculty of Medicine, Canada’s top-ranked medical school.
“In dermatology, it’s critical to have the diagnostic equipment required to provide quick, reliable results for patients in a pain-free way – and MedX delivers this like no other, thanks to their rigorous standards for safety and quality,” said Dr. Champagne. “MedX is a leader in teledermatology because they listen to the dermatology community to develop effective, forward-thinking tools and software that we as specialists, and our patients, need most. I’m honoured to be appointed Chair of the Advisory Board and look forward to working together with this well-respected team to take teledermatology to the next level.”
With both a Doctor of Medicine degree from Western University and a Master of Science, Health Systems Research from the University of Toronto, Dr. Champagne’s expertise spans dermatology and computer science. He has been particularly instrumental in the development of DermSecure®, MedX’s Patient Management Software, ensuring that it interacts efficiently and effectively with a dermatologist’s workflow. He is also overseeing exciting new developments in Artificial Intelligence (AI) functionality, an area of rapid growth, which he will continue to guide in the years to come.
“We’re very proud to have a leader of Dr. Champagne’s calibre as the first Chair of our Scientific and Medical Advisory Board,” said Mike Druhan, President, Dermatology Services and Products. “His continued leadership and foresight will ensure we are in lockstep with the needs of the dermatology community, not only improving patient care and outcomes today but anticipating and meeting future needs. We are all driven to save lives.”
About MedX MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also embedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain-free, non-invasive manner, with its software than creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA, TGA, and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey. Visit https://medxhealth.com .
Investor Relations Contact: Bill Mitoulas Email: [email protected] Tel: +1.416.479.9547
Posted by AGORACOM-JC
at 8:13 PM on Monday, December 14th, 2020
Highlights:
MedX partners with national telehealth leader IVPG in the Netherlands
Two skin screening clinics opened in November 2020, with more than 800 assessments on close to 500 patients completed to date using MedX’s DermSecure ® platform
Three additional clinics to come online in the Netherlands by the end of December 2020
IVPG plans to expand to 41 skin assessment clinics by 2022
More than half of all cancers reported in the Netherlands are skin cancers
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX), a global leader in teledermatology, announces that it has begun the rollout of DermSecure ® , MedX’s skin screening telemedicine platform, across the Netherlands in partnership with national telehealth leader The Netherlands Institute for Prevention and Health (“IVPG”).
“Telehealth allows us to assess patients, relay test results and provide video consultations with IVPG doctors, ultimately offering greater access to medical specialists during the COVID-19 crisis,” commented Paul Vlaanderen, IVPG Founder & CEO. “This improved access to healthcare specialists has directly resulted in higher quality care and the ability for patients to play a greater role in their healthcare management. We opened two locations in November and experienced substantial interest in the skin screening service, completing over 800 assessments on nearly 500 patients so far, and the DermSecure platform worked flawlessly. We will add another three locations, Rotterdam, Utrecht and Den Haag, to our IVPG network in 2020. IVPG further plans to bring the total number of scanning centers to 41 by 2022.”
“According to the World Cancer Research Fund, the Netherlands is ranked fifth globally for melanoma skin cancer. We know that early detection of skin cancer results in lower mortality rates, lower health care costs and much better patient outcomes. MedX’s advanced imaging technology and secure, scalable, teledermatology platform was a perfect fit to address the need for rapid skin screening in the Netherlands,” continued Mr. Vlaanderen.
Naman Demaghlatrous, MedX’s Managing Director, Europe, Middle East and Africa, was very impressed with the results of the implementation, stating, “Building on our pilot project with IVPG, DermSecure ® provides the requisite security and scalability to open multiple centers and expand this partnership significantly. We are honoured to work with Mr. Vlaanderen as he has been a pioneer in championing telehealth in the Netherlands. We look forward to playing a crucial role in enhancing Netherlanders’ access to early screening and thereby reduce skin cancer deaths.”
About MedX
MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy ® on DermSecure ® telemedicine platform, utilizing its SIAscopy ® technology. SIAscopy ® is also embedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain-free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA, TGA and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com
About IVPG
IVPG is a Netherlands based Institute for Prevention and Health using telehealth for the delivery of digital healthcare. We are a collaboration of doctors and specialists. Together we help the Dutch to live a healthy and energetic life. IVPG provides the Dutch people with health information, free preventive examinations and advice to give more in-depth insight into their health. Although we are not always in control of our health, we can often manage it. That is our commitment. www.ivpg.nl
Forward-Looking Statements
This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company’s limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company’s projections or forward-looking statements. All forward-looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.
Posted by AGORACOM-JC
at 8:20 AM on Monday, November 30th, 2020
Company reported revenue of $172,889 for the three months ended September 30, 2020, compared with revenue of $234,977 for the three months ended September 30, 2019.
Revenue from SIAscopy ® of $74,286 for the third quarter was 29% higher than the prior year three-month period and more than twice that of the three months ending June 30, 2020.
Revenue from the Company’s therapeutic laser line of $98,603 was a decrease from $177,436 in the prior year period, but $60,180 higher than in the prior three month period.
MedX Health Corp. (“MedX” or “Company”) (TSX-V: MDX) announced its results for the three and nine-months ended September 30, 2020, which are also available on SEDAR ( www.sedar.com ).
The Company reported revenue of $172,889 for the three months ended September 30, 2020, compared with revenue of $234,977 for the three months ended September 30, 2019. Revenue from SIAscopy ® of $74,286 for the third quarter was 29% higher than the prior year three-month period and more than twice that of the three months ending June 30, 2020. Revenue from the Company’s therapeutic laser line of $98,603 was a decrease from $177,436 in the prior year period, but $60,180 higher than in the prior three month period. The Company reported a loss for the three months ended September 30, 2020 of $1,083,772 or $0.01 per share compared with a loss of $577,648, or $0.00 per share for the three months ended September 30, 2019.
The Company reported revenue of $337,885 for the nine months ended September 30, 2020, compared with revenue of $678,886 for the nine months ended September 30, 2019. Revenue from SIAscopy ® of $127,093 was 21% higher than in the first nine months of 2019. Revenue from the Company’s therapeutic laser line of $210,792 for the nine-month period was 63% lower than the $574,069 in the prior year period. The Company reported a loss for the nine months ended September 30, 2020 of $2,532,171 or $0.02 per share, compared with a loss of $2,086,892, or $0.01 per share for the nine months ended September 30, 2019.
“We are pleased that we had strong revenue growth in Q3 compared to Q2, as we more than doubled revenue in each of our product lines,” noted Rob von der Porten, Executive Chairman, and acting CEO. “We made our first shipment of SIAscopy ® units to our Brazilian distribution partner, where they will be deployed on our DermSecure ® platform over the coming months. The sales and marketing team are building a pipeline of international distribution partners for our SIAscopy ® on DermSecure ® telemedicine platform and are experiencing strong interest in the Company’s unique teledermatology platform. While COVID-19 will continue to have an impact on all businesses, it is increasing the interest in telemedicine in general, albeit it is impacting the rate of implementation. While our revenue increased over the second quarter, the loss for the quarter was higher as we built out our sales team, increased marketing efforts, and spent on continued enhancements to our DermSecure ® platform, and as well, we incurred non-cash share-based compensation expense. We remain convinced that we will have long-term, sustainable growth with the MedX DermSecure ® platform and that it is the ‘Gold Standard’ in the teledermatological market space.”
The Company also announces that 800,000 stock options have been granted to Directors. Such options have an exercise price of $0.17 per share, will expire on November 25, 2025, and vest immediately.
MedX also announces it has retained Venture North Capital Inc. (“Venture North”) for strategic marketing, investor relations and capital markets communications services. Venture North will arrange and attend meetings with professional investors, maintain ongoing contact and broaden relationships with the professional investment community on MedX’s behalf.
Under the terms of the agreement, MedX will pay Venture North a monthly fee of $6,000 for ongoing strategic services for an initial six (6) months, after which the relationship will continue on a monthly basis. The agreement may be terminated by MedX or Venture North on 60 days written notice. Venture North will also be granted stock options (the “Options”), totaling up to 900,000 common shares of the Company, which will vest and become exercisable quarterly with 225,000 of the options vesting on each of the dates that are three, six, nine and twelve months from the beginning of the Engagement Period. The Options will be exercisable at a price of $0.17 per share for a period of two years. The appointment and option grant are subject to TSX Venture Exchange approval.
Summary of Recent Announcements:
The following is a summary of recent announcements made by the Company, for which further details can be found under the Company’s profile at www.sedar.com .
MedX Announces Sales Agency Agreement with Ziemer Professional Corp.
On October 28, 2020, the Company announced it had completed a sales agency agreement with the Ziemer Professional Corporation. Ziemer will target its sales efforts within the medical, athletic, and pain management clinic markets. Six new clinics will begin installing the SIAscopy ® on Dermsecure ® telemedicine platform across Ontario and Saskatchewan.
MedX Adds Two New Members to Board of Directors
On October 15, 2020, the Company appointed Anthony Milonas and Wayne Cockburn as Directors of the Company. Mr. Milonas and Mr. Cockburn bring extensive senior management experience working with medical device and health care growth-stage companies, both nationally and internationally. Mr. Milonas is President and CEO of Canadian Orthodontic Partners, a company overseeing a national network of orthodontic practices. Mr. Cockburn is President of The Clinic Network Canada, one of Canada’s largest providers of out-of-hospital pain management services.
MedX Expands Senior Leadership Team
On September 21, 2020, the Company announced the appointment of veteran healthcare industry executive Naman Demaghlatrous as Managing Director, Europe, Middle East & Africa (“EMEA”), and Chantal Ward, RN, as Director, Dermatological Services. Mr. Demaghlatrous brings more than 20 years of experience in the healthcare industry, including roles with companies such as Medtronic, Pediapharm, Johnson & Johnson and Atfal Pharma. Chantal Ward, RN, a Diploma Nurse Graduate with an operating room background, has 20+ years’ experience as a clinical trainer of advanced medical aesthetic equipment and technology.
MedX Announces Management Changes and Increased Focus on SIAscopy® on DermSecure®
On September 9, 2020, the Company announced management changes to enhance its focus on its dermatological services and products including DermSecure ® and SIAscopy ® . Mike Druhan, who has championed SIAscopy ® within the Company for a number of years, has been appointed President, Dermatological Services and Products. Louie Canitano, who has many years of experience in therapeutic laser and light products has been appointed Managing Director, Light Therapy Products.
MedX Announces Closing of Non-Brokered Private Placement
On August 4, 2020, the Company announced that further to the Conditional Approval from the TSX Venture Exchange for a non-brokered Private Placement to accredited investors of up to 16,666,666 units at $0.12 per unit (“Unit”), to raise up to $2,000,000, the closing of a first tranche of that placement has taken place on July 31, 2020, for a total of 2,600,000 units, raising a total of $312,000. Each Unit is comprised of One (1) fully paid common share and One (1) Share Purchase Warrant, exercisable to purchase One (1) further Common Share at the price of $0.20, exercisable for a period of two years from the date of issue. The securities issued will be restricted from trading for four months from the date of issue. In connection with this tranche of the private placement, cash commissions of $24,000 were paid.
About MedX
MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy ® on DermSecure ® telemedicine platform, utilizing its SIAscopy ® technology. SIAscopy ® is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA, TGA and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com .
This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company’s limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company’s projections or forward-looking statements. All forward looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Posted by AGORACOM-JC
at 7:31 AM on Thursday, November 12th, 2020
Will be presenting at this year’s virtual Fall Investor Summit on Tuesday, November 17th at 4:00PM (EST) / 1:00PM (PST), and will host virtual one-on-one meetings with interested investors throughout the conference, which runs November 16 -18.
NEW YORK, NY / November 12, 2020 / MedX Health Corp. (“MedX”, or the “Company”) (TSXV:MDX), a Company focused on becoming the leader in teledermatology, will be presenting at this year’s virtual Fall Investor Summit on Tuesday, November 17th at 4:00PM (EST) / 1:00PM (PST), and will host virtual one-on-one meetings with interested investors throughout the conference, which runs November 16 -18. To register, or to schedule a virtual one-on-one meeting, visit https://investorsummitgroup.com/.
During the presentation, MedX’s CEO, Robert von der Porten, and Mike Druhan, President, Dermatology Products & Services, will provide an overview of the Company’s fully integrated telemedicine platform specializing in dermatology and how its platform is being deployed to revolutionize skin cancer detection methods.
The Fall Investor Summit will take place virtually, featuring 75 companies and over 300 institutional and retail investors.
ABOUT MEDX:
MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy™ on DermSecure™ telemedicine platform, utilizing its SIAscopy™ technology. SIAscopy™ is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA, TGA and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.
ABOUT THE INVESTOR SUMMIT:
The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE